Oppenheimer Maintains Outperform on Monopar Therapeutics, Raises Price Target to $115
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
Oppenheimer analyst Andreas Argyrides maintains Monopar Therapeutics (NASDAQ:MNPR) with a Outperform and raises the price target from $77 to $115.
Oppenheimer analyst Andreas Argyrides maintains Monopar Therapeutics (NASDAQ:MNPR) with a Outperform and raises the price target from $77 to $115.